Response to the FDA Draft Guidance for Industry document: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (Docket 2006D-0044)
Year: 2006
Type: article
Abstract: We would like to express our appreciation to the FDA for this well-written document, which presents a strong and cohesive argument for the use of PRO tools in clinical research as well as useful guidance on the sound application of PRO assessment in clinical trials.QualityMetric and Health Assessment Lab strongly support the overall goal of the
Source: eScholarship@UMassChan
Authors: Jakob B. Bjorner, Barbara Gandek, Jason C. Cole, Mark Kosinski, Gene V. Wallenstein, Milena Anatchkova, John E. Ware
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W1520303921
